31 December 2016
Todd started his Biotech fund at Marketocracy in March, 2011. His returns have averaged 24.94% since then, which compares nicely to the S&P 500’s 11.84% return over the same period. Over the last five and three year periods, he did better than the top U.S. Equity fund manager. Before taking anyone’s investment advice, you should always check out their track record. Here is Todd’s.
Ken Kam: Todd, can you tell me a little bit about the stocks you recommended this summer, and how they have done?
Todd Hagopian: During a period of instability surrounding the election, while the S&P was barely up at all, this group of four recommendations has really performed well as a whole. Here were the results:
- Cara Therapeutics (CARA) is up 52.9% since I first recommended it in September.
- Zynerba Pharmaceuticals (ZYNE) is up 27.6% since I first recommended it in September.
- GW Pharmaceuticals (GWPH) is up 17.3% since I first recommended it in July.
- INSYS Therapeutics (INSY) is down 13.8% since I first recommended it in June.